Horizon Funds Horizon Digital Frontier ETF YNOT 深 滬
等待開盤 12-18 09:30:00 美东时间
27.4225
-0.622
-2.22%
華盛通- 最 高28.05
- 今 開28.05
- 成交量 3639股
- 最 低 27.4225
- 昨 收 28.045
- 總市值 5731.30万
- 52周最高 30.47
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 25.08
- 委 比 69.23%
- 總股本 209.00万
- 歷史最高 30.47
- 量 比 1.90
- 振 幅 2.24%
- 歷史最低 25.08
- 每 手 1
- 風險率 1.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Reports Operational Progress In TACTI-004 Phase III Trial Evaluating Eftilagimod Alfa In Combination With MSD's Anti-PD-1 Therapy, KEYTRUDA, And Chemotherapy As First Line Therapy For Advanced/Metastatic Non-Small Cell Lung Cancer
The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial's targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries
12-16 21:02
Pfizer And Astellas Pharma Announce FDA Approval For PADCEV, Nectin-4 Directed ADC, In Combination With PD-1 Inhibitor Keytruda Or Keytruda QLEX, For Certain Patients With Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with
11-22 02:30
Merck Keytruda formulations approved in U.S. for bladder cancer
The U.S. Food and Drug Administration (FDA) on Friday approved injectable and intravenous versions of Merck’s (MRK) blockbuster anti-PD-1 therapy Keytruda for bladder cancer as part of a combination r...
11-22 01:42
Investors Sitting On Cash? This New ETF Offers Modern Alternative
New SBIL ETF offers cash-equivalent solution with flexibility and stability. Perfect for risk-averse investors seeking real yield and full liquidity.
07-15 21:03
YNOT Invest In Tech? Horizon's New ETFs Balance Innovation And Risk
Horizon introduces 2 new ETFs, taking total to 9. QGRD aims for Nasdaq-100 exposure with downside protection, while YNOT invests in digital firms.
07-15 04:33
